National Vision Holdings, Inc. Reports Second Quarter 2023 Financial Results

• Net revenue of $525.3 million, an increase of 3.1% from Q2 2022
• Comparable store sales growth of (0.1%) and Adjusted Comparable Store Sales Growth of 1.0% from Q2 2022
• Net income of $5.6 million and Diluted EPS of $0.07 compared with $9.7 million and $0.12, respectively in Q2 2022
• Adjusted Operating Income of $16.4 million compared with $27.8 million in Q2 2022
• Adjusted Diluted EPS of $0.17 compared with $0.21 in Q2 2022

DULUTH, Ga.–(BUSINESS WIRE)–National Vision Holdings, Inc. (NASDAQ: EYE) (“National Vision” or the “Company”) today reported its financial results for the second quarter ended July 1, 2023.

“We delivered second quarter 2023 results generally in line with our expectations, reflecting continued strength in our managed care business and progress on our strategic initiatives, including expanding exam capacity through enhanced optometrist retention and recruitment efforts,” said Reade Fahs, National Vision’s CEO. “As we look ahead, we remain focused on better serving our customers, enhancing our market position and driving long-term growth of our America’s Best and Eyeglass World brands. While we continue to navigate near-term headwinds, we believe National Vision remains well positioned to achieve our full-year 2023 guidance and deliver sustainable profitable growth over the long term.”

This release includes certain Non-GAAP Financial Measures that are not recognized under generally accepted accounting principles (“GAAP”). Please see “Non-GAAP Financial Measures” and “Reconciliation of Non-GAAP to GAAP Financial Measures” below for more information.

Second Quarter 2023 Summary

• Net revenue increased 3.1% to $525.3 million compared with the second quarter of 2022 primarily due to growth from new store sales and an increase in Adjusted Comparable Store Sales Growth, partially offset by the effect of unearned revenue in the second quarter of 2023 compared with the prior-year quarter. Net revenue includes a (0.9%) impact from the timing of unearned revenue in the current-year quarter compared with the prior-year quarter.
• Comparable store sales growth was (0.1%) and Adjusted Comparable Store Sales Growth was 1.0%, both reflecting higher average ticket and an increase in customer transactions. Comparable store sales growth was negatively impacted by the effects of unearned and deferred revenue in the current-year quarter compared with the prior-year quarter.
• The Company opened 24 new stores, closed one store, and ended the quarter with 1,381 stores. Overall, store count grew 5.1% from July 2, 2022 to July 1, 2023.
• Costs applicable to revenue increased 5.7% to $247.8 million compared with the second quarter of 2022. As a percentage of net revenue, costs applicable to revenue increased 120 basis points to 47.2% compared with the second quarter of 2022 and were primarily driven by an increase in optometrist-related costs partially offset by increased exam revenue. In addition, costs applicable to revenue as a percentage of net revenue increased due to lower product protection plan revenue as well as other product mix and margin effects.
• Selling, general and administrative expenses (SG&A) increased 7.1% to $244.0 million compared with the second quarter of 2022. Adjusted SG&A increased 6.3% to $238.0 million compared with the second quarter of 2022. As a percentage of net revenue, SG&A increased 170 basis points to 46.4% compared with the second quarter of 2022 mainly due to increases in performance-based incentive and stock-based compensation, payroll, and occupancy expense offset primarily by a decrease in other expenses. As a percentage of net revenue, adjusted SG&A increased 140 basis points to 45.3% compared with the second quarter of 2022, driven by increases in payroll, performance-based incentive compensation, and occupancy expense, partially offset by a decrease in other expenses.
• Depreciation and amortization expense of $24.9 million decreased 1.3% from the prior-year period primarily due to a shift to cloud-based software investments that are amortized in SG&A, partially offset by the Company’s ongoing investments in remote medicine technology and new store openings.
• Net income decreased 42.3% to $5.6 million compared with the second quarter of 2022. Net income margin decreased 80 basis points to 1.1% compared with the second quarter of 2022.
• Diluted earnings per share (EPS) decreased 40.8% to $0.07 compared with the second quarter of 2022. Adjusted Diluted EPS decreased 19.1% to $0.17 compared with the second quarter of 2022. The change in margin on unearned revenue negatively impacted Diluted EPS by $0.03 and Adjusted Diluted EPS by $0.03.
• Adjusted Operating Income decreased 40.8% to $16.4 million compared with the second quarter of 2022. Adjusted Operating Margin decreased 240 basis points to 3.1% compared with the second quarter of 2022. The change in margin on unearned revenue negatively impacted net income by $2.6 million and Adjusted Operating Income by $3.5 million.

Six Months Year-to-Date Summary

• Net revenue increased 4.9% to $1,087.7 million compared with the same period of 2022 and was primarily driven by growth from new store sales, an increase in Adjusted Comparable Store Sales Growth, higher revenue from the Company’s AC Lens business and the effect of unearned revenue in the current period compared with the prior-year period. Net revenue includes a 0.6% impact from the timing of unearned revenue in the current-year period compared with the prior-year period.
• Comparable store sales growth was 1.5% and Adjusted Comparable Store Sales Growth was 0.9%, both reflecting higher average ticket and an increase in customer transactions.
• The Company opened 32 new stores, closed six stores, and ended the period with 1,381 stores.
• Costs applicable to revenue increased 6.6% to $501.9 million compared with the same period in 2022. As a percentage of net revenue, compared with the prior-year period, costs applicable to revenue increased 70 basis points to 46.1%, mainly due to an increase in optometrist-related costs partially offset by increased exam revenue and the effects from increased eyeglass mix and higher eyeglass margin. In addition, costs applicable to revenue as a percentage of net revenue increased due to lower product protection plan revenue.
• SG&A increased 8.2% to $493.9 million compared with the same period in 2022. Adjusted SG&A increased 8.2% to $483.6 million compared with the same period of 2022. As a percentage of net revenue, SG&A increased 140 basis points to 45.4% compared with the same period in 2022 mainly due to increases in performance-based incentive and stock-based compensation and payroll, partially offset by lower advertising expense. As a percentage of net revenue, adjusted SG&A increased 140 basis points driven by increases in performance-based incentive compensation and payroll, partially offset by lower advertising expense​.
• Depreciation and amortization expense of $49.7 million decreased 1.3% from the prior-year period primarily due to a shift to cloud-based software investments that are amortized in SG&A, partially offset by the Company’s ongoing investments in remote medicine technology and new store openings.
• Net income decreased 40.1% to $23.9 million compared with the same period in 2022. Net income margin decreased 160 basis points to 2.2% compared with the same period in 2022.
• Diluted EPS decreased 36.0% to $0.30 compared to the same period in 2022. Adjusted Diluted EPS decreased 4.4% to $0.51 compared to the same period in 2022. The net change in margin on unearned revenue benefited Diluted EPS by $0.04 and Adjusted Diluted EPS by $0.04.
• Adjusted Operating Income decreased 22.9% to $56.3 million compared with the same period of 2022. Adjusted Operating Margin decreased 180 basis points to 5.2% compared with the same period in 2022. The net change in margin on unearned revenue benefited net income by $3.5 million and Adjusted Operating Income by $4.7 million.

Balance Sheet and Cash Flow Highlights as of July 1, 2023

• National Vision’s cash balance was $254.6 million as of July 1, 2023. The Company had no borrowings under its $300.0 million first-lien revolving-credit facility (“Revolving Loans”), exclusive of letters of credit of $6.4 million.
• Total debt was $565.7 million as of July 1, 2023, consisting of outstanding first-lien term loans, convertible senior notes (“2025 Notes”) and finance lease obligations, net of unamortized discounts.
• Cash flows from operating activities for the first six months of 2023 were $112.2 million compared to $88.0 million for the second quarter of 2022. The year-over-year increase was primarily due to timing of incentive compensation-related payments.
• Capital expenditures for the first six months of 2023 totaled $54.1 million compared to $55.7 million for the second quarter of 2022.
• As previously announced in June 2023, National Vision entered into an amended credit agreement, extending its access to $300.0 million in liquidity through Revolving Loans for an additional five years through June 13, 2028.

Share Repurchase Program

In the second quarter of 2023, the Company did not repurchase any shares of its common stock. Year to date through July 1, 2023, National Vision repurchased approximately 1.1 million shares for $25.0 million. The Company has $25.0 million remaining under its current share repurchase authorization.

Recent Development

As previously announced on July 26, 2023, the Company’s partnership with Walmart Inc. (“Walmart”) will be ending in 2024. This includes supplying and operating Vision Centers in select Walmart stores, providing contact lens distribution and related services to Walmart and its affiliate, and arranging for the provision of optometric services at certain Walmart locations in California. In connection with the termination of these agreements, National Vision expects to record noncash goodwill and intangible asset impairment charges of approximately $60 million and $10 million, respectively, in the third quarter of 2023.

Fiscal 2023 Outlook

National Vision’s fiscal 2023 outlook reflects current expected or estimated impacts related to macro-economic factors, including inflation, geopolitical instability and risks of recession, as well as constraints on exam capacity; however, the ultimate impact of these factors on the Company’s financial outlook remains uncertain with dynamic market conditions and the outlook shown below assumes no material deterioration to the Company’s current business operations as a result of such factors or as a result of the termination of the Walmart partnership.

Based on its financial results for the six months ended July 1, 2023, and outlook for the remainder of this fiscal year, National Vision is reaffirming its fiscal-2023 guidance as provided on May 11, 2023 for all metrics except for depreciation and amortization, which the Company now expects to be in a range of $99 million to $101 million from the previous range of $104 million to $106 million. National Vision also noted that based on its year-to-date performance, it expects Adjusted Operating Income and Adjusted Diluted EPS to be at or above the midpoint of its fiscal 2023 guidance range.

The fiscal 2023 outlook information provided above includes Adjusted Operating Income and Adjusted Diluted EPS guidance, which are non-GAAP financial measures management uses in measuring performance. The Company is not able to reconcile these forward-looking non-GAAP measures to GAAP without unreasonable efforts because it is not possible to predict with a reasonable degree of certainty the actual impact of certain items and unanticipated events, including taxes and non-recurring items, which would be included in GAAP results. The impact of such items and unanticipated events could be potentially significant.

The fiscal 2023 outlook is forward-looking, subject to significant business, economic, regulatory and competitive uncertainties and contingencies, many of which are beyond the control of the Company and its management, and based upon assumptions with respect to future decisions, which are subject to change. Actual results may vary and those variations may be material. As such, the Company’s results may not fall within the ranges contained in its fiscal 2023 outlook. The Company uses these forward-looking measures internally to assess and benchmark its results and strategic plans. See “Forward-Looking Statements” below.

Conference Call Details

The Company will host a conference call to discuss its second quarter 2023 financial results and fiscal-year 2023 guidance today, August 10, 2023, at 8:30 a.m. Eastern Time. To pre-register for the conference call and obtain a dial-in number and passcode please refer to the “Investors” section of the Company’s website at www.nationalvision.com/investors. A live audio webcast of the conference call will be available on the “Investors” section of the Company’s website at www.nationalvision.com/investors, where presentation materials will be posted prior to the conference call. A replay of the audio webcast will also be archived on the “Investors” section of the Company’s website.

About National Vision Holdings, Inc.

National Vision Holdings, Inc. is the second largest optical retail company in the United States (by sales) with more than 1,300 retail stores in 44 states and Puerto Rico. With a mission of helping people by making quality eye care and eyewear more affordable and accessible, the Company operates five retail brands: America’s Best Contacts & Eyeglasses, Eyeglass World, Vision Centers inside select Walmart stores, and Vista Opticals inside select Fred Meyer stores and on select military bases, and several e-commerce websites, offering a variety of products and services for customers’ eye care needs.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934. These statements include, but are not limited to, statements contained under “Recent Development” and “Fiscal 2023 Outlook” as well as other statements related to our current beliefs and expectations regarding the performance of our industry, the Company’s strategic direction, market position, prospects including remote medicine and optometrist recruiting and retention initiatives, and future results. You can identify these forward-looking statements by the use of words such as “outlook,” “guidance,” “believes,” “expects,” “potential,” “continues,” “may,” “will,” “should,” “could,” “seeks,” “projects,” “predicts,” “intends,” “plans,” “estimates,” “anticipates” or the negative version of these words or other comparable words. Caution should be taken not to place undue reliance on any forward-looking statement as such statements speak only as of the date when made. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law. Forward-looking statements are not guarantees and are subject to various risks and uncertainties, which may cause actual results to differ materially from those implied in forward-looking statements. Such factors include, but are not limited to, the COVID-19 pandemic and future resurgences, and related impacts including federal, state, and local governmental actions in response thereto; customer behavior in response to the pandemic, including the impact of such behavior on in-store traffic and sales; market volatility and an overall decline in the health of the economy and other factors impacting consumer spending, including inflation and uncertainty in financial markets (including as a result of recent bank failures and events affecting financial institutions); our ability to recruit and retain vision care professionals for our stores and remote medicine offerings in general and in light of the pandemic; our ability to compete successfully; our ability to successfully open new stores and enter new markets; our ability to expand our remote medicine offerings and electronic health records capabilities; our ability to maintain the performance of our Host and Legacy brands and our current operating relationships with our Host and Legacy partners; our ability to successfully navigate the termination of our Walmart partnership, including the transition period; our ability to maintain sufficient levels of cash flow from our operations to execute or sustain our growth strategy or obtain additional financing at satisfactory terms or at all; the impact of wage rate increases, inflation, cost increases and increases in raw material prices and energy prices; our growth strategy straining our existing resources and causing the performance of our existing stores to suffer; our ability to successfully and efficiently implement our marketing, advertising and promotional efforts; risks associated with leasing substantial amounts of space, including future increases in occupancy costs; the impact of certain technological advances, and the greater availability of, or increased consumer preferences for, vision correction alternatives to prescription eyeglasses or contact lenses, and future drug development for the correction of vision-related problems; our ability to retain our existing senior management team and attract qualified new personnel; our ability to manage our inventory; seasonal fluctuations in our operating results and inventory levels; risks associated with our e-commerce and omni-channel business; the loss of, or disruption in the operations of, one or more of our distribution centers and/or optical laboratories, resulting in the inability to fulfill customer orders and deliver our products in a timely manner; risk of losses arising from our investments in technological innovators in the optical retail industry; risks associated with environmental, social and governance issues, including climate change; risks associated with vendors from whom our products are sourced, including our dependence on a limited number of suppliers; our ability to develop, maintain and extend relationships with managed vision care companies, vision insurance providers and other third-party payors; our ability to effectively operate our information technology systems and prevent interruption or security breach; our reliance on third-party coverage and reimbursement, including government programs, for an increasing portion of our revenues; our ability to adhere to extensive state, local and federal vision care and healthcare laws and regulations; our compliance with managed vision care laws and regulations; our ability to adhere to changing state, local and federal privacy, data security and data protection laws and regulations; product liability, product recall or personal injury issues; our failure to comply with, or changes in, laws, regulations, enforcement activities and other requirements; the impact of any adverse litigation judgments or settlements resulting from legal proceedings relating to our business operations; our ability to adequately protect our intellectual property; our significant amount of indebtedness and our ability to generate sufficient cash flow to satisfy our debt obligations; a change in interest rates as well as changes in benchmark rates and uncertainty related to the foregoing; restrictions in our credit agreement that limits our flexibility in operating our business; potential dilution to existing stockholders upon the conversion of our convertible notes; and risks related to owning our common stock (including the timing, manner and volume of repurchases of common stock pursuant to our share repurchase program), including our ability to comply with requirements to design and implement and maintain effective internal controls. Additional information about these and other factors that could cause National Vision’s results to differ materially from those described in the forward-looking statements can be found in filings by National Vision with the Securities and Exchange Commission (“SEC”), including our latest Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, which are accessible on the SEC’s website at www.sec.gov. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and in our filings with the SEC.

Non-GAAP Financial Measures

To supplement the Company’s financial information presented in accordance with GAAP and aid understanding of the Company’s business performance, the Company uses certain non-GAAP financial measures, namely “EBITDA,” “Adjusted Operating Income,” “Adjusted Operating Margin,” “Adjusted EBITDA,” “Adjusted EBITDA Margin,” “Adjusted Diluted EPS,” “Adjusted Comparable Stores Sales Growth,” “Adjusted SG&A,” and “Adjusted SG&A Percent of Net Revenue.” We believe EBITDA, Adjusted Operating Income, Adjusted Operating Margin, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Diluted EPS, Adjusted SG&A and Adjusted SG&A Percent of Net Revenue assist investors and analysts in comparing our operating performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance. Management believes these non-GAAP financial measures are useful to investors in highlighting trends in our operating performance, while other measures can differ significantly depending on long-term strategic decisions regarding capital structure, the tax jurisdictions in which we operate and capital investments. Management uses these non-GAAP financial measures to supplement GAAP measures of performance in the evaluation of the effectiveness of our business strategies, to make budgeting decisions, to establish discretionary annual incentive compensation and to compare our performance against that of other peer companies using similar measures.

Contacts

Investor:
Angie McCabe

investor.relations@nationalvision.com

Media:
Racheal Peters

media@nationalvision.com

Read full story here